NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a biotechnology company specializing in the development of improved cancer treatments targeting the tumor microenvironment (MET), today announces that it has raised additional tranches of funding from its funding agreement with Atlas Special Opportunities, LLC (ASO), for an aggregate amount of €2,375,000 and issued 2,419 convertible bonds (including 44 convertible bonds issued in connection with transaction costs) with a nominal value of €1,000 each. The remaining availability under the agreement with ASO extends the company’s financial visibility until December 2022.